CANNABIS EN TÊTE A propos du Dossier Central publié dans le N°237 de la Revue SANTÉ MENTALE "SCHIZOPHRÉNIE ET CANNABIS" - - - - - - - - - - DOPAMINE #05 (MAI 2019) Sans créer de lien de causalité à la vas-vite, difficile de ne pas associer schizophrénie et usage de cannabis puisqu'un quart des patients souffrants de cette pathologie consomment régulièrement un produit qui n'est peut-être pas entré dans leur vie par hasard ou du moins qu'ils ont adopté pour soulager certains symptômes tout en en aggravant d'autres... Quant à la part de responsabilité du cannabis dans l'apparition d'une schizophrénie, un certain nombre [...]
Lire la suiteEfficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study Vanina Popova, M.D., Ella J. Daly, M.D., Madhukar Trivedi, M.D., Kimberly Cooper, M.S., Rosanne Lane, M.A.S., Pilar Lim, Ph.D., Christine Mazzucco, M.Sc., David Hough, M.D., Michael E. Thase, M.D., Richard C. Shelton, M.D., Patricio Molero, M.D., Ph.D., Eduard Vieta, M.D., Ph.D., Malek Bajbouj, M.D., Husseini Manji, M.D., Wayne C. Drevets, M.D., Jaskaran B. Singh, M.D. American Journal of Psychiatry in Advance, 2019 ajp.psychiatryonline.org doi: 10.1176/appi.ajp.2019.19020172 Objective : About one-third of patients with depression fail to achieve remission despite treatment with multiple [...]
Lire la suiteCannabis thérapeutique : «Tous les voyants sont au vert» Par Charles Delouche — 29 mai 2019 à 18:50 Libération Alors que l’Agence nationale du médicament doit rendre son projet d'expérimentation du cannabis thérapeutique fin juin, le Sénat a débattu du sujet ce mercredi à l’initiative d’Esther Benbassa, sénatrice EE-LV de Paris. Battre le fer tant qu’il est chaud. C’est l’idée qui animait le débat sans vote qui s’est déroulé ce mercredi au Sénat autour du cannabis thérapeutique à l'initiative d'Esther Benbassa, sénatrice Europe Ecologie-les Verts (EE-LV) de Paris. La veille, une conférence de presse était organisée aux côtés de [...]
Lire la suiteCannabidiol, a Cannabis sativa constituent, as an antipsychotic drug A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira and F.S. Guimarães Brazilian Journal of Medical and Biological Research, 2006, 39, 421-429 ISSN 0100-879X Review Abstract A high dose of Δ9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of Δ9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The [...]
Lire la suiteDissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity Matthew B. Wall, Rebecca Pope, Tom P. Freeman, Oliwia S. Kowalczyk, Lysia Demetriou, Claire Mokrysz, Chandni Hindocha, Will Lawn, Michael A.P. Bloomfield, Abigail M. Freeman, Amanda Feilding, David J. Nutt and H. Valerie Curran Journal of Psychopharmacology, 2019, 1–9 DOI: 10.1177/0269881119841568 journals.sagepub.com/home/jop Abstract Background : Two major constituents of cannabis are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the main psychoactive component; CBD may buffer the user against the harmful effects of THC. Aims : We examined the effects of two strains of cannabis and placebo on the human brain’s resting-state networks [...]
Lire la suitePsychedelic therapy in the Czech Republic : A theoretical concept or a realistic goal ? Zuzana Postranecka, Čestmir Vejmola and Filip Tyls Journal of Psychedelic Studies DOI: 10.1556/2054.2019.003 Abstract Psychedelic research has been associated with the Czech Republic since the early 19th century and, after a long period of involuntary dormancy, it has recently gained new opportunities to follow up on its roots and evolve. This article briefly describes the history of psychedelic research in the Czech Republic, summarizes the role of the UN Drug Conventions, and discusses the Czech and international legislation pertaining to psychedelics. The discussion focuses on the dependence/abuse potential of classical [...]
Lire la suiteCannabis for refractory epilepsy in children : a review focusing on CDKL5 Deficiency Disorder Tristan Dale, Jenny Downs, Heather Olson, Ann Marie Bergin, Stephanie Smith and Helen Leonard Epilepsy Research, 2019 DOI: https://doi.org/doi:10.1016/j.eplepsyres.2019.02.001 Abstract Severe paediatric epilepsies such as CDKL5 Deficiency Disorder (CDD) are extremely debilitating, largely due to the early-onset and refractory nature of the seizures. Existing treatment options are often ineffective and associated with a host of adverse effects, causing those that are affected to seek alternative treatments. Cannabis based products have attracted significant attention over recent years, primarily driven by reports of miraculous cures and a renewed public preference for ‘natural’ therapies, [...]
Lire la suiteExtractions of Medical Cannabis Cultivars and the Role of Decarboxylation in Optimal Receptor Responses Melissa M. Lewis-Bakker, Yi Yang, Rupali Vyawahare, and Lakshmi P. Kotra Cannabis and Cannabinoid Research, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0067 Abstract Introduction : Phytocannabinoids, characteristic compounds produced by medical cannabis, interact with cannabinoid (CB) receptors (CB1 and CB2) as well as other receptor systems to exhibit their corresponding pharmacological effects. In their natural form, CBs such as D9-tetrahydrocannabinolic acid and cannabidiolic acid are inactive at these receptors, while their decarboxylated forms (D9 tetrahydrocannabinol and cannabidiol, respectively) are potent ligands at CB receptors. Thus, extraction and processing [...]
Lire la suiteCannabis Chemovar Nomenclature Misrepresents Chemical and Genetic Diversity; Survey of Variations in Chemical Profiles and Genetic Markers in Nevada Medical Cannabis Samples Ulrich Reimann-Philipp, Mark Speck, Cindy Orser, Steve Johnson, Aaron Hilyard, Helen Turner, Alexander J. Stokes, and Andrea L. Small-Howard Cannabis and Cannabinoid Research, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0063 Abstract Introduction : Medical cannabis patients receive clinical benefits from the secondary metabolites of the plant, which contain a variety of cannabinoids and terpenoids in combinations that can be used to classify the chemovars. State-regulated medical cannabis programs rely on breeder-reported ‘‘strain’’ names both within diversion control systems and to [...]
Lire la suitePotency Analysis of Medical Marijuana Products from New York State Lingyun Li, Bryan C. Duffy, Lorie A. Durocher, Mark A. Dittmar, Robert A. Acosta, Emily R. Delaney, Lei Li, Kenneth M. Aldous and David C. Spink Cannabis and Cannabinoid Research, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0037 Abstract Introduction : In the United States, medicalmarijuana programs have been established in 29 states and the District of Columbia. In 2014, New York State (NYS) approved medical marijuana legislation, and its program became fully operational in January of 2016. Products manufactured under the auspices of the program may be used by certified patients in [...]
Lire la suite